Orexo confirms that Meda has initiated the launch the drug EdluarTM in the United States of America. The launch follows the US Food and Drug Administration's (FDA) approval in March this year of EdluarTM 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
The details can be read here.
No comments:
Post a Comment